This retrospective multicenter cohort study (48 Japanese institutions, 2016–2022) compared treatment strategies — upfront gastrectomy vs. upfront chemotherapy, and various multimodal sequences — in 1,181 gastric cancer patients with positive peritoneal lavage cytology (CY1) and/or localized peritoneal metastasis (P1a), with no other distant metastases. The primary outcome was overall survival (OS).
The overall 5-year OS was 25.0% (median survival 24.3 months). Upfront gastrectomy showed better OS than upfront chemotherapy (5-year OS 27.6% vs. 19.0%; HR 0.80; P = .004), but chemotherapy followed by gastrectomy after conversion to P0CY0 yielded the best outcomes of any strategy (5-year OS 50.5%), compared to 31.4% for upfront gastrectomy plus postoperative chemotherapy; gastrectomy alone and chemotherapy alone had poor 5-year OS rates of 10.3% and 3.2%, respectively.
Retrospective design with inherent selection bias — patients who achieved conversion to P0CY0 likely had more chemotherapy-sensitive disease; treatment allocation was not randomized, so direct strategy comparisons are confounded by patient and tumor characteristics not fully adjusted for.
For gastric cancer with CY1 and/or P1a, multimodal therapy is essential — neither surgery nor chemotherapy alone is adequate. When feasible, pursuing preoperative chemotherapy to achieve P0CY0 conversion before gastrectomy appears to offer the best survival, making development of more effective perioperative regimens a priority.
Explore related topics